Skip to menu Skip to content Skip to footer

1998

Conference Publication

Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial

Brener, SJ, Barr, LA, Cohen, ED, White, HJ, Moliterno, DJ, Cheek, HB, Effron, MB and Topol, EJ (1998). Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83942-3

Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial

1998

Conference Publication

Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORT

Brener, SJ, Ellis, SG, Burchenal, JEB, Katz, S, Effron, MB and Topol, EJ (1998). Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORT. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84709-2

Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORT

1998

Conference Publication

Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting

Kleiman, NS, Graziadei, N, Lance, E, Maresh, K, Taylor, J, Higginbotham, J, Edwards, A, Effron, MB, Mascelli, MA and Jordan, RE (1998). Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84740-7

Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting

1998

Conference Publication

Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3)

Tcheng, JE, Kereiakes, DJ, George, BS, Braden, G, Langrall, MA, Zelinger, D, Jordan, R and Effron, MB (1998). Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3). NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83944-7

Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3)

1998

Conference Publication

Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial

Barr, LA, Brener, SJ, Jones, AA, Moliterno, DJ, Effron, MB and Topol, EJ (1998). Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84737-7

Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial

1997

Conference Publication

Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results

Ellis, SG, Serruys, PW, Popma, JJ, Teirstein, PS, Ricci, DR, Gold, HK and Effron, MB (1997). Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results. DALLAS: AMER HEART ASSOC.

Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results